Retinal Biologics Market – By Drug Class (VEGF-A Antagonist, TNF-a Inhibitor) Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Global Forecast (2024 – 2032)

Retinal Biologics Market Size

Retinal Biologics Market size was valued at USD 23.4 billion in 2023 and is anticipated grow at a CAGR of 8.2% between 2024 and 2032, driven by increasing prevalence of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy. Growing aging populations coupled with higher rates of diabetes contribute to this growth.
 

Additionally, advancements in treatment options, such as longer-lasting therapies and combination treatments that enhance patient outcomes and convenience increase the adoption of retinal biologics therapies, further enhancing market growth. Moreover, robust R&D efforts focused on expanding indications for existing biologics as a potential breakthrough for genetic retinal disorders, is contributing to the market growth.
 

Retinal biologics refers to biological therapies or drugs that are specifically used to treat diseases and conditions affecting the retina, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, among others. Biologics are typically derived from living organisms and are designed to target specific molecules or pathways involved in disease processes. They may include monoclonal antibodies or proteins that can inhibit certain growth factors or other mediators involved in retinal diseases. Examples of retinal biologics include anti-vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, and aflibercept, which are used to treat macular degeneration and other retinal conditions.
 

Retinal Biologics Market Trends

• Retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are becoming more common globally. Factors such as aging populations and higher rates of diabetes contribute to this increase.
   
• For instance, as per the International Diabetes Foundation, in 2021 approximately 537 million people were living with diabetes and the number of people with diabetes is projected to rise to 643 million and 783 million by 2030 and 2045 respectively. As the prevalence of these conditions rises, so does the demand for effective treatments to manage them.
   
• Retinal biologics, such as anti-VEGF therapies, have become a standard of care for many retinal diseases, providing targeted treatments that improve patient outcomes. Thus, with growing patient population, there is a substantial demand for effective treatment options, thereby driving the market growth.
   
• Additionally, there is a strong focus on research and development (R&D) in the field of retinal biologics as companies strive to improve existing treatments and develop new therapies. This includes efforts to create biologics with longer durations of action, reducing the frequency of treatments for patients. These R&D efforts drive innovation, lead to the introduction of new products, and increase the range of treatment options available in the market, fostering growth and competition.
   

Retinal Biologics Market Analysis

Based on drug class, the market is segmented into VEGF-A antagonist and TNF-a inhibitor. The VEGF-A antagonist segment was valued at USD 16.4 billion in 2023.
 

• VEGF-A antagonists have been extensively studied in clinical trials and have demonstrated strong efficacy and safety profiles. As a result, these therapies have received regulatory approvals for multiple indications, reinforcing their position as a standard of care in treating retinal diseases.
   
• The widespread adoption of these treatments, results in high market penetration.
   
• Additionally, patient satisfaction and demand for effective treatments that preserve vision and improve quality of life contribute to the dominance of VEGF-A antagonists in the market.
   

Based on indication, the retinal biologics market is classified into macular degeneration, diabetic retinopathy, uveitis, and other indications. In 2023, the macular degeneration segment held significant market share of 40.1%.
 

• Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss in geriatric population, driving significant demand for effective treatments. The increasing prevalence of AMD, coupled with the growing elderly population globally, thus fuels the demand for retinal biologics.
   
• Additionally, ongoing advancements in biologic drug development and delivery systems are enhancing treatment efficacy and patient outcomes, further solidifying macular degeneration's prominent position in the market.
   

Based on distribution channel, the retinal biologics market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to witness growth at CAGR of 8.3% between 2024 – 2032.
 

• Hospital pharmacies hold the highest market share in the market due to their ability to offer centralized access to biologics for patients undergoing treatment for retinal diseases. They provide efficient distribution and availability of these therapies to inpatients and outpatients, while also ensuring specialized handling, storage, and administration according to strict safety protocols.
   
• Additionally, expert pharmacists and staff at hospital pharmacies provide specialized support and guidance to both patients and healthcare providers, enhancing the quality of care. These factors contribute to the dominance of hospital pharmacies in the market.
   

North America retinal biologics market size in 2023 was valued at USD 9.7 billion and is predicted to grow at a CAGR of 8.0% over the analysis timeframe.

• North America holds the highest market share in the market due to its advanced healthcare infrastructure and high prevalence of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy.
   
• Early adoption of new medical technologies and treatments, as well as a supportive regulatory environment, encourages the introduction and acceptance of advanced therapies in the region.
   
• Additionally, high healthcare expenditure and presence of leading pharmaceutical companies actively engaged in research and development of retinal biologics, further drives the regional market growth.
   

U.S. retinal biologics market is projected to reach USD 17.4 billion by the end of forecast period.
 

• The U.S. has a significant aging population, leading to a higher prevalence of retinal diseases such as age-related macular degeneration (AMD). For instance, as per the Centers for Disease Control and Prevention, approximately 19.8 million Americans aged above 40 years and above were living with age-related macular degeneration (AMD) in 2019.
   
• This creates substantial demand for effective treatments, including retinal biologics, thereby driving the growth of this market.
   

Germany retinal biologics market is expected to grow significantly over the coming years.
 

• Germany is a major hub for pharmaceutical research and development. Leading pharmaceutical companies and biotechnology firms in the country are actively engaged in the development and production of retinal biologics, contributing to market growth.
   
• Furthermore, the growing prevalence of retinal diseases due to an aging population increases demand for effective treatments such as retinal biologics, thus fueling the market growth.
   

Japan is anticipated to witness lucrative growth in the retinal biologics market.
 

• Japan has one of the world's most rapidly aging populations, leading to an increased prevalence of retinal diseases. For instance, according to the Ministry of Internal Affairs and Communications, 36.2 million people aged 65 and over are living in Japan in 2023. This demographic trend drives demand for effective treatments like retinal biologics.
   
• Additionally, highly advanced healthcare system in the country with specialized ophthalmology centers and hospitals, further increases the adoption of retinal biologics in the country.
   

Retinal Biologics Market Share

The retinal biologics industry is characterized by the presence of leading pharmaceutical and biopharmaceutical companies. The key market players include F-Hoffman La Roche Ltd., Novartis AG, and AbbVie Inc. which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.
 

Retinal Biologics Market Companies

Prominent players operating in the retinal biologics industry include:

• AbbVie Inc.
• Amgen Inc.
• Janssen Pharmaceuticals (Johnson & Johnson)
• F-Hoffman La Roche Ltd.
• Oxurion NV
• Novartis AG
• MeiraGTx Limited
• Regeneron Pharmaceuticals Inc.
• OncoGene Pharmaceuticals
• SemaThera Inc.
   

Retinal Biologics Industry News:

• In March 2024, Roche launched Vabysmo (faricimab) in India for treating neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). This product launch helped the company to strengthen their customer base and product portfolio.
   
• In August 2023, Regeneron Pharmaceuticals announced the FDA approval of EYLEA HD (aflibercept) injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). This strategic initiative helped the company to broaden their product offerings and generate revenue.
   

The retinal biologics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• VEGF-A antagonist
• TNF-a inhibitor

Market, By Indication

• Macular degeneration
• Diabetic retinopathy
• Uveitis
• Other indications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa